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 95 
ABSTRACT 96 
The current clinical dogma assumes that urine is sterile in the absence of 97 
clinically relevant infection. However, recent evidence has demonstrated the existence of 98 
a female urinary microbiota in women with and without lower urinary tract symptoms. 99 
With the knowledge that the lower urinary tract possesses its own unique microbiota, I 100 
hypothesize that certain bacterial species of the female microbiota may be the cause or 101 
play a role in lower urinary tract syndromes, such as overactive bladder syndrome 102 
(OAB). About 40-50% of OAB patients do not respond to conventional anti-muscarinic 103 
and beta-3 adrenergic agonist drug treatment. One possible explanation for this lack of 104 
treatment response is a dysbiosis of urinary microbiota. To determine if women with 105 
OAB have a dysbiotic urinary microbiota, our group developed an expanded quantitative 106 
urine culture (EQUC) protocol to culture transurethral catheter urine specimens obtained 107 
from women with and without OAB. EQUC revealed differences in the female urinary 108 
microbiota in women with and without OAB. Given evidence of planktonic bacteria in 109 
the urine, I hypothesized that bacteria also may be associated with the urothelium. To test 110 
this hypothesis, I examined urothelial cells shed into urine for the presence of adherent 111 
and/or intracellular bacteria. I used a new protocol that was able to determine which 112 
bacteria associate with shed urothelial cells, but could not distinguish between adherent 113 
or intracellular bacteria. By identifying differences in the urinary microbiota between 114 
women with different disease/health states, and by determining which of those bacteria 115 
  viii 
associate with the urothelium, one can begin to understand how the female urinary 1 
microbiota could contribute to lower urinary tract disorders. 2 
  1 
 1 
CHAPTER ONE 2 
INTRODUCTION 3 
Urinary health disorders affect many people. For example, overactive bladder 4 
syndrome (OAB) affects about 15% of adult women with increasing incidence with age 5 
(Hartmann et al., 2009). The exact etiology of OAB is not known, but one cause is 6 
thought to be a neuro-muscular dysfunction; thus, the treatment options for OAB are the 7 
administration of anti-muscarinic drugs or beta-3 adrenergic receptor agonists to relieve 8 
the symptoms (Michel & Chapple, 2009). However, the side effects (such as severe dry 9 
mouth or urinary retention) can be uncomfortable for the patient and only 50-60% of 10 
patients have their symptoms resolved (Santos & Telo, 2010, Chapple et al., 2013). Since 11 
anti-muscarinic and beta-3 adrenergic agonist treatments aimed at relaxing the bladder 12 
are ineffective in a large percentage of OAB sufferers, it is likely that there are etiologies 13 
outside of neuro-muscular dysfunction (Nitti et al., 2010).  14 
Emerging DNA sequencing and culture evidence indicates that microbial 15 
communities exist within the bladder (Siddiqui et al., 2011, Fouts et al., 2012, Nelson et 16 
al., 2012, Wolfe et al., 2012, Khasriya et al., 2013, Lewis et al., 2013, Brubaker et al., 17 
2014, Hilt et al., 2014, Pearce et al., 2014). With this evidence that bacterial DNA 18 
(microbiome) and live bacteria (microbiota) exist within the bladders of women with 19 
OAB and of women without OAB, it is possible that microbes represent a new etiology 20 
  
2 
or a contributing factor for OAB. For example, women who do not respond to OAB 1 
therapies might not suffer from OAB; instead, a causative or contributing bacterium 2 
might not be a known uropathogen or it might be present at lower colony forming units 3 
(CFU)/mL than the threshold of 105 CFU/mL used in standard practice since the 1950s 4 
(Kass, 1956, Kass, 1957). Alternatively, women who do not respond may have a 5 
dysbiosis of their microbiota. How bacteria cause OAB symptoms is not known, but 6 
bacteria present in the bladder could interact with the urothelium such that the detrusor 7 
urinae muscle is induced to contract and initiate, exacerbate or propagate OAB 8 
symptoms.  9 
 The overall hypothesis of this present study was that the female urinary 10 
microbiota are different in women with and without OAB. The aims to address the 11 
overall hypothesis of the present study were to: (1) isolate and identify the bacteria that 12 
comprise the female urinary microbiota and (2) determine if the bacterial species of the 13 
female urinary microbiota are associated with the human urothelium.  14 
  
3 
LITERATURE REVIEW 15 
Female Lower Urinary Tract Biology  16 
 The lower urinary tract consists of the following anatomical sites: the ureters, the 17 
bladder, and the urethra. In a female, the ureters connect the renal pelvis to the bladder, 18 
which is then connected to the vulva by the urethra (Martini FH, 2009).   19 
 The ureters are muscular tubes that extend inferiorly from the renal pelvis and 20 
penetrate the posterior wall of the bladder where urine is deposited.  The bladder is a 21 
hollow muscular organ that functions as a temporary storage unit for urine. When the 22 
bladder is empty, it is decompressed; as the bladder fills with urine, it takes on a spherical 23 
shape. The area of the bladder where the urethra attaches is known as the trigone. This 24 
trigone acts as a funnel that channels urine through the urethra as the bladder contracts. 25 
The urethra, which is about 3-5 cm in females, connects the neck of the bladder to the 26 
vulva or exterior (Martini FH, 2009). 27 
 Each anatomical site has its own characteristic histology. The ureters consist of 28 
three layers: an inner mucosa lining also known as urothelium, a muscular layer made up 29 
of smooth muscle, and an outer connective tissue layer (Martini FH, 2009, Birder & 30 
Andersson, 2013). The bladder also contains three layers. First, there is the mucosa layer, 31 
comprised of the urothelium and the lamina propria (Martini FH, 2009, Birder & 32 
Andersson, 2013). Next is the muscularis propria, which contains the detrusor urinae 33 
muscle; when contracted, it compresses the bladder to expel the urine into the urethra 34 
(Martini FH, 2009, Birder & Andersson, 2013). Finally there is the adventitia/serosa layer 35 
composed of connective tissue (Martini FH, 2009, Birder & Andersson, 2013). At the 36 
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junction of the bladder and urethra, there is a circular band of skeletal muscle known as 37 
the urethral sphincter that remains in a relaxed muscle state until it is voluntarily 38 
contracted to allow urination. The urethra is lined with a transitional epithelium and is 39 
surrounded by layers of smooth muscle (Martini FH, 2009).    40 
The detrusor urinae muscle can be stimulated by a variety of receptors by both the 41 
parasympathetic and sympathetic nervous systems (Martini FH, 2009).  Two types of 42 
receptors are stimulated via the parasympathetic nervous system: the cholinergic nicotinic 43 
and muscarinic receptors; both are stimulated by the neurotransmitter acetylcholine 44 
(ACh), which induces an activation or contraction effect on the detrusor urinae muscle 45 
(Martini FH, 2009). The type of receptor stimulated via the sympathetic nervous system 46 
is the adrenergic beta-receptor. The adrenergic beta-receptor is stimulated by the 47 
neurotransmitters epinephrine and norepinephrine and has an inhibitory or relaxation 48 
effect on the detrusor urinae muscle (Martini FH, 2009, Goldenberg, 2012). 49 
Recent evidence shows urothelial cells that comprise the urothelium can be 50 
stimulated via the same receptors found on the detrusor urinae muscle. These receptors 51 
include the adrenergic beta-receptors and the cholinergic nicotinic and muscarinic 52 
receptors. Thus, urothelial cells can both be targets of these receptors’ neurotransmitters 53 
and release various mediators to influence detrusor urinae muscle cell contraction (Birder 54 
& Andersson, 2013). 55 
 56 
  
5 
History of Clinical Microbiology Urine Culture 57 
The current clinical dogma assumes that urine is sterile in the absence of 58 
clinically relevant infection. Since the 1950’s, the clinical practice for detecting infection 59 
in the bladder, including urinary tract infection, cystitis and pyelonephritis, has been 60 
based on a method that detects bacterial species present in mid-stream urine at greater 61 
than or equal to 105 colony forming units (CFU)/mL (Kass, 1956, Kass, 1957). However, 62 
this threshold of ≥105 CFU/mL was not designed to detect infection in the bladder. 63 
Instead, it was originally set as a threshold to detect kidney infection or pyelonephritis 64 
(Kass, 1956, Kass, 1957), which is characterized by chills, fever, flank pain and dysuria 65 
(Beeson, 1955, Kass, 1956). In the 1950’s, Dr. Edward Kass, an infectious disease 66 
physician, sought a method to prevent post-operative sepsis in patients undergoing kidney 67 
surgery. To achieve his goal, he needed a reliable test that could detect uropathogens in 68 
urine collected via a non-invasive procedure. He chose midstream urine and identified the 69 
threshold of ≥105 CFU/mL as adequate for the task (Kass, 1956, Kass, 1957).  70 
Yet, many studies have provided evidence that this threshold is insufficient to 71 
detect significant infection of the lower urinary tract in all types of patient populations 72 
(Stamm et al., 1982, Stark & Maki, 1984, Lipsky et al., 1987, Maskell, 2010, Hooton et 73 
al., 2013, Khasriya et al., 2013). Dr. William Stamm (1982) demonstrated that 102 of a 74 
known uropathogen in the midstream urine of women was indicative of lower urinary 75 
tract infection (Stamm et al., 1982), while Dr. Benjamin Lipsky (1987) showed that a 76 
threshold of 103 CFU/mL of a known uropathogen in midstream urine was indicative of 77 
lower urinary tract infection in men (Lipsky et al., 1987).  Similarly, Dr. Randall Stark 78 
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(1984) determined that a bacterium present at lower than 105 CFU/mL was indicative of 79 
lower urinary tract infection in catheterized patients (Stark & Maki, 1984).  80 
At about the same time, Dr. Rosalind Maskell (1981-1988) performed 81 
scientifically rigorous studies that provided compelling evidence to disprove the dogma 82 
that urine was sterile in the absence of a clinically relevant infection (Maskell, 2010). In 83 
one of her studies, Dr. Maskell collected supra-pubic aspirate (SPA) urine specimens 84 
from women suffering from a whole host of lower urinary tract disorders, including 85 
dysuria and interstitial cystitis (Maskell, 2010). She then plated the SPA samples and 86 
incubated the plates in different conditions for a longer period. She explained: 87 
“Overnight incubation in air of cultures on a primary isolation medium   88 
does   not   detect   organisms   other   than   the   aerobic pathogens.   Many   89 
organisms   with   other   requirements, for example   anaerobes   and   CO2- 90 
requiring   bacteria   and   those species   that   need   longer   incubation, are   91 
well   recognised   as pathogens   in   sites   other   than   the   urinary   tract 92 
(Maskell, 2010)” 93 
Dr. Maskell showed the presence of bacteria in these SPA samples and hypothesized that 94 
other bacterial species are likely present in the urinary tract. She further hypothesized that 95 
it is either a dysbiosis of commensal flora and/or an unknown uropathogen that is causing 96 
these women to suffer from lower urinary tract disorders other than a urinary tract 97 
infection (UTI) (Maskell, 2010). 98 
Dr. Maskell was not the only one to hypothesize that bacteria may influence 99 
symptoms in lower urinary tract disorders. Dr. Thomas Hooton and colleagues (2013) 100 
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obtained transurethral catheter (TUC) specimens from women suffering from cystisis 101 
and found evidence of many Gram-positive bacteria, such as lactobacilli, staphylococci, 102 
streptococci and Gardnerella vaginalis (Hooton et al., 2013). Hooton and colleagues did 103 
not go into detail about whether these Gram-positive bacteria are a consequence or a 104 
cause of cystitis, but they did suggest a re-evaluation of the use of midstream urine 105 
cultures to make an accurate diagnosis of a patient with lower urinary tract symptoms and 106 
to consider the idea the bladder possesses a resident bacteria flora (Hooton et al., 2013). 107 
 108 
Overactive Bladder Syndrome 109 
Urinary health disorders affect many people. For example, overactive bladder 110 
syndrome (OAB) affects about 15% of adult women with increasing incidence with age 111 
(Hartmann et al., 2009). OAB is characterized by symptoms of urinary urgency, often 112 
with frequency and urgency incontinence, nocturia and a negative standard urine culture 113 
(Haylen et al., 2010).  114 
The exact etiology of OAB is not known, but one cause is thought to be a 115 
neurological disorder due to increased release of the neurotransmitter ACh, which binds 116 
to cholinergic nicotinic and cholinergic muscarinic receptors on the detrusor urinae 117 
muscle and causes contractions and the feeling of urgency (Martini FH, 2009, Michel & 118 
Chapple, 2009).  119 
One treatment for OAB is the administration of anti-muscarinic drugs (e.g., 120 
Solifenacin) to prevent the binding of ACh to the cholinergic muscarinic receptor and 121 
therefore relieve the symptoms (Michel & Chapple, 2009, Nitti et al., 2010). However, 122 
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uncomfortable side effects (such as severe dry mouth) are causes for reduced 123 
compliance. Furthermore, only 50-60% of patients have their symptoms resolved 124 
(responders), while 40-50% of patients retain symptoms (non-responders) (Santos & 125 
Telo, 2010). 126 
Another more recent treatment option for OAB is the administration of a beta-3 127 
adrenergic receptor agonist known as Mirabegron. This agonist binds to beta-3 adrenergic 128 
receptors and causes the detrusor muscle to relax (Goldenberg, 2012, Afeli et al., 2013). 129 
This relaxation of the detrusor muscle counteracts the overstimulation of cholinergic 130 
muscarinic receptors. However, a major side effect with Mirabegron is urinary retention 131 
due to too much relaxation of the detrusor muscle (Goldenberg, 2012). Moreover, the 132 
response rate to Mirabegron is similar to that of Solifenacin (Chapple et al., 2013, 133 
Abrams et al., 2014). 134 
Since both anti-muscarinic and beta-3 adrenergic agonist treatments aimed at 135 
relaxing the bladder are ineffective in a large percentage of OAB sufferers, it is likely that 136 
there are etiologies and/or causes outside of neuro-muscular dysfunction (Nitti et al., 137 
2010).  138 
 139 
The Female Urinary Microbiome/Microbiota 140 
Recent DNA sequencing and culture evidence reveals the presence of microbial 141 
communities within the bladder (Siddiqui et al., 2011, Fouts et al., 2012, Nelson et al., 142 
2012, Wolfe et al., 2012, Khasriya et al., 2013, Lewis et al., 2013, Brubaker et al., 2014, 143 
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Hilt et al., 2014, Pearce et al., 2014). These data demonstrate the existence of the 144 
urinary microbiome (bacterial DNA) and the urinary microbiota (live bacteria). 145 
Various investigators have used culture-independent 16S rRNA gene sequencing 146 
to acquire evidence of diverse bacteria that are not routinely cultured by clinical 147 
microbiology laboratories in the mid-stream urine of women and men (Nelson et al., 148 
2010, Dong et al., 2011, Siddiqui et al., 2011, Nelson et al., 2012).  149 
Wolfe and co-workers (2012) went a step further, providing definitive evidence of 150 
bacterial DNA in the bladders of women. They used 16S rRNA gene sequencing to 151 
identify bacterial DNA present in ‘culture-negative’ urine specimens collected from 152 
women diagnosed with pelvic organ prolapse and/or urinary incontinence and from 153 
women without urinary symptoms. In this study, urine was collected via three methods: 154 
clean, catch midstream voided (MV), transurethral catheter (TUC) and suprapubic 155 
aspirate (SPA). The bacterial DNA communities detected in paired TUC and SPA 156 
samples were similar, while the MV samples contained a mixture of urinary and genital 157 
tract bacterial communities. Because the SPA samples were obtained directly from the 158 
bladder, these researchers concluded that urine in the bladder contained bacterial DNA. 159 
Since the SPA and TUC samples were similar, they concluded that TUC samples were 160 
representative of bacterial communities present in the bladder (Wolfe et al., 2012). 161 
 162 
Intracellular Bacteria and Urothelium 163 
Many bacterial species reported to cause UTI colonize the urinary tract. The only 164 
way to successfully colonize is to associate with the urothelium. A key step in 165 
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pathogenesis for major uropathogens, such as Proteus mirabilis, Klebsiella 166 
pneumoniae, and Escherichica coli, is their association with the urothelium (Coker et al., 167 
2000, Struve et al., 2008, Hunstad & Justice, 2010). In the case of Klebsiella pneumoniae 168 
and Escherichia coli, they both express type 1 fimbriae that attach to urothelial cell 169 
receptors; this allows them to be taken up intracellularly (Struve et al., 2008, Hunstad & 170 
Justice, 2010). Proteus mirabilus expresses many types of fimbriae, which permits it to 171 
attach to diverse urothelial cell receptors (Pearson et al., 2008). Other bacterial species 172 
shown to associate with the urothelium and reported to cause a UTI include 173 
Streptococcus agalactiae or Group B Streptococcus (GBS) and Enterococcus faecalis 174 
(Ulett et al., 2010, Horsley et al., 2013). 175 
Bacterial species that associate with the urothelium are of interest because they 176 
are likely to play a role in lower urinary tract disorders such as OAB. With evidence of a 177 
urinary microbiota (Hilt et al., 2014) and evidence that certain bacterial species associate 178 
with shed uroepithelial cells in the urine (Horsley et al., 2013, Khasriya et al., 2013), it is 179 
reasonable to hypothesize that some of these bacteria associate with the urothelium and 180 
that these associations may play a role in lower urinary tract disorders.  181 
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CHAPTER TWO 1 
METHODS AND MATERIALS 2 
Patients and Sample Collection: Following Loyola institutional review board (IRB) 3 
approval for all phases of this project, participants gave verbal and written consent for the 4 
collection and analysis of their urine for research purposes. Participants were women 5 
undergoing OAB treatment and a comparison group of women undergoing benign 6 
gynecologic surgery (controls). Participants' symptoms were characterized with the 7 
Pelvic Floor Distress Inventory (PFDI), a self-completed, validated symptom 8 
questionnaire (Barber et al., 2006). All participants were without clinical evidence of 9 
urinary tract infection (i.e., standard urine culture negative and absence of clinical UTI 10 
diagnosis). Urine was collected via transurethral catheter from participants for the period 11 
March 2013 to April 2014 at the Female Pelvic Medicine and Reconstructive Surgery 12 
center of Loyola University Medical Center. A portion of each urine sample was placed 13 
in a BD Vacutainer Plus C&S Preservative Tube (Becton Dickinson and Co; Franklin 14 
Lakes, NJ)	  and sent to the clinical microbiology lab for quantitative culture. A separate 15 
portion of the urine sample, to be used for sequencing, was placed at 4°C for no more 16 
than 4 h following collection. To this portion, 10% AssayAssure (Thermo Scientific; 17 
Waltham, MA)	  was added before freezing at −80°C. 18 
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Standard Urine Culture: The clinical microbiology laboratory staff processed each 1 
catheterized urine sample using the standard culture procedure. Standard urine culture 2 
was performed by inoculating 0.001 ml of urine onto a 5% sheep blood agar plate (BAP) 3 
and MacConkey agars (BD BBL™ Prepared Plated Media, Becton Dickinson and 94 Co; 4 
Sparks, MD) and streaking the entire plate surface to obtain quantitative colony counts. 5 
The plates were incubated aerobically at 35°C for 24 h (Figure 1). Each separate 6 
morphological colony type was counted and identified in any amount. The detection level 7 
was 103 CFU/ml, represented by 1 colony of growth on either plate. If no growth was 8 
observed, the culture was reported as “no growth” (of bacteria at lowest dilution, i.e., 9 
1:1000). 10 
Expanded Quantitative Urine Culture (EQUC): Each catheterized urine sample also was 11 
processed using the EQUC procedure (Hilt et al., 2014). For EQUC, 0.1 ml of urine was 12 
inoculated onto BAP, chocolate and colistin, and nalidixic acid (CNA) agars (BD BBL™ 13 
Prepared Plated Media), streaked for quantitation, and incubated in 5% CO2 at 35°C for 14 
48 h. A second set of BAPs, were each inoculated with 0.1 ml of urine and incubated in 15 
room atmosphere at 35°C and 30°C for 48 h. Next, 0.1 ml of urine was inoculated onto 16 
each of two CDC anaerobe 5% sheep blood agar plates (BD BBL™ Prepared Plated 17 
Media) and incubated in either a Campy gas mixture (5% O2, 10% CO2, 85% N) or under 18 
anaerobic conditions at 35°C for 48 h. The detection level was 10 CFU/ml, represented 19 
by 1 colony of growth on any of the plates. Finally, to detect any bacterial species that 20 
may be present at quantities lower than 10 CFU/ml, 1.0 ml of urine was placed in 21 
thioglycolate medium (BD BBL™ Prepared Tubed Media) and incubated aerobically at   22 
  
13 
 23 
 24 
Figure 1-Outline of Standard Urine and Expanded Quantitative Urine Culture 25 
  26 
  
14 
35°C for 5 days. If growth was visually detected in the thioglycolate medium, the 27 
medium was mixed and a few drops were plated on BAP and CDC anaerobe 5% sheep 28 
blood agars for isolation and incubated aerobically and anaerobically at 35°C for 48 h 29 
(Figure 1). Each morphologically distinct colony type was isolated on a different plate of 30 
the same media to prepare a pure culture that was used for identification. Because no 31 
unique bacterial species were detected in three of the EQUC conditions (Campy Gas 32 
mixture-5% O2, 10% CO2, 85% N at 37°C for 48 hours, Aerobic at 30°C for 5 days, and 33 
Thioglycolate medium Aerobic for 5 days), I removed those conditions from the EQUC 34 
protocol as of December 2013  35 
Identification of Pure Isolates: Matrix assisted laser desorption ionization–time of flight 36 
mass spectrometry (MALDI-TOF MS) was used to identify each morphologically distinct 37 
colony. The direct colony method was performed. Using toothpicks, we applied a small 38 
portion of a single isolated colony to the surface of a 96-spot, polished, stainless steel 39 
target plate (Bruker Daltonik GmbH, Leipzig, Germany) in a manner that created a thin 40 
bacterial film. The spot was left to dry at room temperature for 1 min., whereupon 1.0 µl 41 
of 70% formic acid was applied to each sample and allowed to dry at room temperature 42 
for 10 min. Then, 1.0 µl of the matrix solution, comprised of saturated α-cyano-4- 43 
hydrocinnamic acid (Bruker Daltonik) in an organic solvent (High-Pressure Liquid 44 
Chromatography-Mass Spectrometry [HPLC-MS]-grade water, 100% Trifluoroacetic 45 
Acid, and Acetonitrile; Fluka) was then applied to each sample and allowed to 46 
cocrystallize at room temperature for 10 min. The prepared sample target was placed in 47 
the MicroFlex LT mass spectrometer (Bruker Daltonik), and the results were analyzed by 48 
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MALDI Biotyper 3.0 software (Bruker Daltonik). A bacterial quality control strain 49 
(Escherichia coli DH5α) was included in each analysis. A single measurement was 50 
performed once for each culture isolate. 51 
MALDI Data Analyses: MALDI Biotyper 3.0 software Realtime Classification was used 52 
to analyze the samples. In the Realtime Classification program, log score identification 53 
criteria are used as follows. A score between 2.000 and 3.000 is species-level 54 
identification, a score between 1.700 and 1.999 is genus-level identification, and a score 55 
that is below 1.700 is an unreliable identification. A Realtime Classification log score 56 
was given for each bacterial isolate sample for every condition from which it was 57 
isolated. 58 
DNA Isolation, PCR Amplification and 16S rRNA Amplicon Sequencing: Genomic 59 
DNA was extracted from urine using previously validated protocols (Wolfe et al., 2012, 60 
Yuan et al., 2012). Briefly, 1 ml of urine was centrifuged at 13,500 rpm for 10 min and 61 
the resulting pellet was resuspended in 200 µl of filter-sterilized buffer consisting of 20 62 
mM Tris-Cl (pH 8), 2 mM Ethylenediaminetetraacetic Acid (EDTA), 1.2% Triton X-100, 63 
and 20 µg/ml lysozyme and supplemented with 30 µl of filter-sterilized mutanolysin 64 
(5,000 U/ml, Sigma-Aldrich; St. Louis, MO). The mixture was incubated for 1 h at 37°C 65 
and the lysates were processed through the DNeasy blood and tissue kit (Qiagen, 66 
Valencia, CA) according to the manufacturer's protocol. The DNA was eluted into 50 µl 67 
of AE buffer (pH 8.0) and stored at −20°C. The variable region 4 (V4) of the bacterial 68 
16S rRNA gene in each DNA sample was amplified and sequenced using a custom 69 
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protocol developed for the MiSeq desktop sequencer (Illumina; San Diego, CA). 70 
Briefly, the 16S rRNA V4 region was amplified in a two-step nested polymerase-chain 71 
reaction (PCR) protocol using the universal 515F and 806R primers, which were 72 
modified to contain the Illumina adapter sequences. Amplicons were analyzed by gel 73 
electrophoresis and purified using the QIAquick gel extraction kit (Qiagen). Extraction- 74 
and PCR-negative controls were included in all steps to assess potential DNA 75 
contamination. DNA samples were diluted to 10 nM, pooled, and sequenced using the 76 
MiSeq personal sequencer platform using a paired-end 2× 251-bp reagent cartridge. Raw 77 
sequences were processed using the open-source program mothur, v1.31.2 (Kozich et al., 78 
2013). Paired ends were joined and contigs of incorrect length (<285 bp or >300 bp) 79 
and/or contigs that contained ambiguous bases were removed. Sequences were aligned 80 
using the SILVA database, and chimeric sequences were removed with UCHIME (Edgar 81 
et al., 2011). Sequences were classified using a naive Bayesian classifier and the RDP 82 
16S rRNA gene training set (v9). Sequences that could not be classified to the bacterial 83 
genus level were removed from analysis. 84 
Statistical Analyses: Statistical analyses of the microbiota data were performed using 85 
SAS software version 9.3. The frequency of detected genera and species was compared 86 
between groups (OAB v Control), using either Pearson chi-square or Fisher’s exact tests, 87 
depending on assumption validity. The Wilcoxon rank sum tests were used to compare 88 
the median abundance for the cultured genera between groups. No adjustments for 89 
multiple comparisons were made since these analyses were considered descriptive. 90 
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Filtered Urine Culture: Each urine specimen (10 mL) was placed through a filtration 91 
system (Figure 2). The first 5 mL of urine was filtered through a Nucleopore filter with a 92 
pore size 5.0 µm (Whatman). To ensure that free bacteria pass through the filter, a 5.0mL 93 
phosphate buffered saline (PBS) wash was performed. The 5.0 µm filter, which captured 94 
the urothelial cells (20 -100 µm) (Croft et al., 1979, Bostwick & Cheng, 2008), was 95 
placed on a blood plate and incubated in a 5% CO2 incubator at 37°C for 48 hours. The 96 
filtrate, containing planktonic bacteria, was subjected to the EQUC protocol (above in 97 
Materials and Methods). All colonies were counted and any morphologically distinct 98 
colony was isolated onto a fresh plate composed of the same medium to prepare a pure 99 
culture to be used for identification with MALDI-TOF MS. The second 5 mL of urine 100 
was filtered through a Nucleopore filter with a pore size of 0.2 µm, as described above. 101 
All bacteria and urothelial cells were captured on the filter (Hobbie et al., 1977, 102 
Bernhardt et al., 1991). The filter and filtrate from the 0.2 µm arm were handled as 103 
described above.  104 
  105 
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 106 
 107 
Figure 2- Outline of Filtered Urine Culture Protocol 108 
  109 
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Antibiotic Protection Assay: As a control, the EQUC protocol was performed on the 110 
urine samples (as described in Aim 1) to identify the bacterial species present without 111 
treatment. The urine sample (50 mL) was centrifuged at 400 x g at room temperature for 112 
10 minutes. The supernatant was removed and the pellet was washed in 1.0 mL of PBS. 113 
The 1.0 mL of solution was split into two 0.5mL solutions and centrifuged at the same 114 
speed and time. Then, each pellet was re-suspended in either 1.0 mL of PBS or 1.0 mL of 115 
an antibiotic cocktail (200 ug/mL Gentamicin, 100 units/mL Penicillin, 100 mg/mL 116 
Streptomycin) in PBS and then let sit for 2 hours to kill any planktonic or adherent 117 
bacteria. The 1.0 mL solution for each condition was split into two 0.5 mL solutions and 118 
centrifuged at the same speed and time. Then, the pellets either were re-suspended in 1.0 119 
mL of PBS or 1.0 mL of 0.1% Triton-X-100 in PBS and let sit for 5 minutes to lyse the 120 
cells. This procedure resulted in a total of four conditions (PBS-PBS, PBS-Triton X, 121 
Antibiotics-PBS, Antibiotics-Triton X); all four were subjected to the EQUC protocol 122 
(Figure 3). All colonies were counted and any morphologically distinct colony was 123 
isolated onto a fresh plate composed of the same medium to prepare a pure culture for 124 
identification with MALDI-TOF MS 125 
  126 
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 127 
 128 
 129 
Figure 3- Outline of Antibiotic Protection Assay	   130 
  131 
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Human Urothelial Cell/UPEC Infection Assay: An infection assay with an 132 
immortalized human urothelial cell line infected with uropathogenic Escherichia coli 133 
(UPEC) was performed and then subjected to the antibiotic protection assay as a proof of 134 
principle (Figure 4). The infection assay with the immortalized human urothelial cell line 135 
was designed and optimized by Dr. Meghan Pearce. Dr. Phong Lee established the 136 
immortalized human urothelial cell line from a female non-malignant bladder. Four days 137 
prior to infection of urothelial cells, strains of UPEC were streaked onto Lysogeny Broth 138 
(LB) agar and incubated overnight at 37°C. Then a single colony of UPEC strain of 139 
interest was inoculated into 5 mL of liquid LB and incubated overnight at 37°C shaking. 140 
Next, a subculture of 1:1000 of the UPEC into fresh liquid LB was done and allowed to 141 
incubate at 37°C overnight with no shaking. The day before infection, this subculture 142 
process was repeated. To prepare the human urothelial cells, the day before infection, 143 
cells were counted with a hemocytometer and then diluted to 1x105 cells/mL in tissue 144 
culture media.  In triplicate, 1 mL aliquots of urothelial cells were placed into a 24-well 145 
tissue culture treated plate and incubated overnight at 37°C in 5% CO2 to allow the cells 146 
to adhere to the well. The day of infection, the human urothelial cells were examined to 147 
see that they had adhered to the wells. The old media was aspirated out and the cells were 148 
washed 3 times with 1 mL PBS. Then 1.0 mL of Dulbecco’s Modified Eagle Medium: 149 
Nutrient Mixture F-12 (DMEM/F-12)/5% Fetal Bovine Serum (FBS) was added to each 150 
well and allowed to incubate for 30min. To obtain a rough estimate of the multiplicity of 151 
infection (MOI) for UPEC, one well of urothelial cells was trypsinized and the number of 152 
cells  153 
  
22 
 154 
 155 
 156 
Figure 4- Outline of Human Urothelial Cell/UPEC Infection Assay 157 
  158 
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counted. The UPEC culture was either diluted or concentration to so that there would 159 
be 10 UPEC cells for every 1 urothelial cell. Once this UPEC MOI of 10 was prepared, 160 
1.0 mL of this inoculum was added to each of three wells containing urothelial cells. As a 161 
negative control, one well of cells was not inoculated with UPEC. The 24-well plate with 162 
cells was centrifuged at 1400 rpm for 5 min to initiate contact of the UPEC with the 163 
urothelial cells. The plate was incubated at 37°C in 5% CO2 for 2 hours. Once the 2-hour 164 
infection was completed, the cells in each well were trypsinized (1 uninfected well and 3 165 
infected wells) and run separately through the Antibiotic Protection Assay. As a control, 166 
to determine the average intracellular count per well, the infection assay was continued. 167 
First, the human urothelial cells and UPEC were treated for 2 hours with the same 168 
antibiotic cocktail used in the antibiotic protection assay (200 ug/mL Gentamicin, 100 169 
units/mL Penicillin, 100 mg/mL Streptomycin). Second, the cells were washed 3 times 170 
with 1.0 mL of PBS and then treated with 1.0 mL of 0.1% Triton-X-100 in PBS and let 171 
sit for 5 minutes to lyse the cells. Finally, each well was plated with serial dilutions onto 172 
LB agar plates to determine the average intracellular count per well. 173 
 174 
Tissue-Culture Adherence: The following protocol was designed and optimized by Dr. 175 
Meghan Pearce (Figure 5). Each urine sample (20 mL) was centrifuged at 400 x g for 10 176 
minutes. The resultant pellet was then re-suspended in tissue culture media and split into 177 
microtiter plate wells with or without antibiotics (200 ug/mL Gentamicin, 100 units/mL 178 
Penicillin, 100 mg/mL Streptomycin). The plate was then placed in a 5% CO2-enriched 179 
incubator at 37°C for overnight incubation. Observations of human cells, cell debris, and  180 
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 182 
 183 
Figure 5- Outline of Tissue Culture Adherence Assay   184 
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bacteria in the wells were observed the next day. Then, the wells were subjected to a 185 
gentle PBS wash to identify human urothelial cells that remain adherent to the plastic. 186 
Following the wash, 0.5 mL of 0.1% Triton-X-100 was added to the cells for five minutes 187 
to lyse the urothelial cells and the mixture centrifuged at 13,500 rpm for 10 minutes. This 188 
resultant pellet was re-suspended in PBS and plated on a blood agar plate. This blood 189 
agar plate was then be placed in a 5% CO2 incubator at 37°C for 48 hours. All colonies 190 
were counted and any morphologically distinct colony was isolated onto a fresh plate 191 
composed of the same medium to prepare a pure culture to be used for identification with 192 
MALDI-TOF MS. 193 
 194 
Antibiotic Sensitivities of Bacterial Isolates:  For the bacterial isolates that appeared to 195 
be intracellular, a control experiment for antibiotic sensitivity was performed. The 196 
bacterial isolates were tested for sensitivity to the antibiotics used in the cocktail (200 197 
ug/mL Gentamicin, 100 units/mL Penicillin, 100 mg/mL Streptomycin).  198 
 199 
Culture of Bladder Biopsy: Following Loyola institutional review board (IRB) approval 200 
for all phases of this project, participants gave verbal and written consent for the 201 
collection and analysis of their urine and tissue for research purposes. The following 202 
samples were collected from participants: transurethral catheter (TUC) urine, suprapubic 203 
aspirate (SPA) urine and two small tissue biopsies of the bladder urothelium. EQUC was 204 
performed on the TUC and SPA urine samples (as described in Aim 1) to identify the 205 
bacterial species present. The tissue biopsies were washed twice with 1.0 mL of saline. 206 
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After the second wash, each tissue biopsy was ground with a sterile mortar and pestle 207 
in 1.0 mL of saline.  Then 100 µL of the saline mixture was subjected to the EQUC 208 
protocol. 209 
  27 
CHAPTER THREE 1 
ISOLATION AND IDENTIFICATION OF BACTERIA THAT COMPRISE THE 2 
FEMALE URINARY MICROBIOTA 3 
 4 
INTRODUCTION 5 
16S rRNA gene sequence analysis of urine specimens has revealed the existence 6 
of bacterial DNA in urine obtained from women diagnosed with pelvic organ prolapse 7 
and/or urinary incontinence, as well as from women without urinary symptoms or 8 
prolapse. Thus, a female urinary microbiome exists (Wolfe et al., 2012).  9 
In addition, others and we have shown that these bacterial sequences represent 10 
live bacteria; therefore, female urinary microbiota exist (Khasriya et al., 2013, Hilt et al., 11 
2014). These urinary microbiota were detected using expanded versions of the standard 12 
urine culture. Specifically our group developed and performed an expanded quantitative 13 
urine culture (EQUC) on TUC urines to culture bacterial genera detected by 16S rRNA 14 
gene sequencing in previous studies. The bacterial genera being cultured matched the 15 
previous sequencing data demonstrating the presence of a urinary microbiota (Hilt et al., 16 
2014). 17 
With the existence of female urinary microbiota, one needs to determine if they 18 
play a role in lower urinary tract disorders such as OAB. One diagnostic criterion for 19 
OAB is a negative test for UTI - typically a standard urine culture. This culture is when 20 
one inoculates 0.001 mL of urine to blood and MacConkey agar plates and then incubates 21 
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aerobically at 35°C for 24 hours. This standard technique is geared toward detecting 1 
known uropathogens at. the 105 CFU/mL threshold, consistent with the 1950’s intent of 2 
Dr. Kass. Since the previous 16S rRNA sequencing and recent culture data of urine both 3 
demonstrate the presence of bacteria that may not be known uropathogens and/or are 4 
present at levels lower than the threshold, an expanded urine culture technique is needed 5 
to fully assess the differences in the female urinary microbiota of women with and 6 
without OAB. 7 
  8 
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RESULTS 9 
Standard Urine Culture vs. Expanded Quantitative Urine Culture (EQUC) 10 
A total of 189 transurethral catheter urine specimens were collected from 61 11 
women with OAB and 52 women without OAB. All urine specimens were processed 12 
through standard and expanded quantitative urine culture (EQUC) techniques.  13 
Most (153/189) urine specimens grew bacterial species with the EQUC approach. 14 
Yet, 139 of the 153 urine specimens that grew bacterial species were deemed ‘No 15 
Growth’ (Table 1) of bacteria at the lowest dilution, i.e., 1:1000) by the clinical 16 
microbiology lab. These data demonstrate that bacterial species are present in ‘culture- 17 
negative’ urines and the standard urine culture has a false-negative rate of ~90%. One 18 
specimen in particular demonstrates the value of the expanded quantitative culture 19 
(Figure 6).  To date, a total of 608 bacterial isolates that make up 116 diverse bacterial 20 
species have been isolated from these urine specimens (Table 1). The median number of 21 
different bacterial species per urine specimen was three (Table 1).  22 
  23 
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Table 1- Summary of Urine Specimens 24 
 25 
  26 
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 27 
Figure 6- 4-Week OAB Patient Urine. Urine specimen subjected to: (A) Standard 28 
Culture Blood plate incubated 72 hours at 35°C. This routine plate was finalized as ‘No 29 
Growth’ (of bacteria at the lowest dilution of 1:1000) at 24 hours. (B) Expanded Culture 30 
Blood plate incubated 72 hours at 35°C. 31 
32 
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Female Urinary Microbiota in Baseline Urine Specimens in Women with and 33 
without OAB. 	   34 
A subset of 104 baseline urine specimens were subjected to the standard and 35 
expanded quantitative urine cultures, 52 from women without OAB (Control) and 52 36 
from women with OAB. 33 of the 52 (63.46%) control baseline specimens grew bacterial 37 
species, while 45 of the 52 (86.54%) OAB baseline specimens grew bacterial species.  38 
Overall the OAB baseline urine specimens had a greater number of bacterial 39 
isolates than the control baseline urine specimens. Only 82 bacterial isolates were 40 
isolated from the control specimens, whereas 261 bacterial isolates were isolated from the 41 
OAB specimens (p= <0.0001).  The median number of different bacterial species isolated 42 
per control urine specimen was one [Interquartile Range (IQR)=0-2)], while the median 43 
number of different bacterial species isolated per OAB urine specimen was four (IQR=1- 44 
7). 45 
My results show that the OAB female urinary microbiota is richer than the control 46 
female urinary microbiota. To date, 35 unique bacterial species make up the microbiota 47 
of the controls, while 80 unique bacterial species comprise the microbiota of the 48 
symptomatic OAB patients (Figure 7).  49 
  50 
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 51 
Figure 7- Rarefaction Analysis of Unique Bacterial Species. Each unique bacterial 52 
species isolated is documented in each patient cohort as patients are recruited. (OAB 53 
N=52, Control N=52). 35 unique bacterial species comprise the control female urinary 54 
microbiota, while 80 unique bacterial species comprise the OAB female urinary 55 
microbiota. 56 
  57 
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Statistical Analyses of Baseline Urine Cultures of Women with and without OAB.  58 
The Pearson chi-square or Fisher’s exact tests were performed on the subset of 59 
104 baseline urine specimens to determine differences in frequency of the genera and 60 
species isolated in each cohort.  61 
Seven bacterial genera (Actinobaculum, Actinomyces, Aerococcus, 62 
Corynebacterium, Gardnerella, Oligella and Streptococcus) were isolated more 63 
frequently in the OAB cohort compared to the control cohort (Figure 8, Table 2). Three 64 
of these bacterial genera were solely isolated from the OAB cohort (Actinobaculum, 65 
Aerococcus, and Oligella); concentrations ranged from 10 CFU/mL to 100,000 CFU/mL.  66 
The following bacterial species were isolated more frequently in OAB urine 67 
specimens than from control urine specimens: Actinobaculum schaalii, Aerococcus 68 
urinae, Corynebacterium coyleae, Corynebacterium riegelii, Gardnerella vagnialis, 69 
Lactobacillus gasseri, Oligella urethralis, and Streptococcus anginosus (Figure 9, Table 70 
2). The bacterial species Lactobacillus crispatus was isolated more frequently in the 71 
control urine specimens than the OAB urine specimens (Figure 9, Table 2).   72 
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 73 
 74 
Figure 8- Frequency of Bacterial Genera in Each Cohort. Comparison of the 75 
percentage a given bacterial genus was isolated in either an OAB urine specimen (black 76 
bars, N=52 urine specimens) or a control urine specimen (white bars, N=52 urine 77 
specimens). Pearson’s Chi-square and Fisher’s Exact Test were performed to determine 78 
statistically significant differences in isolated bacterial genera (* >0.05, **>0.001). 79 
  80 
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 81 
 82 
Figure 9- Frequency of Bacterial Species in Each Cohort. Percentage a given bacterial 83 
species was isolated in either an OAB urine specimen (black bars, N=52 urine specimens) 84 
or a control urine specimen (white bars, N=52 urine specimens). Pearson’s Chi-square 85 
and Fisher’s Exact Test were performed to determine statistically significantly 86 
differences in isolated bacterial species (* >0.05, **>0.001). 87 
 88 
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Table 2- P-values of Significant Bacterial Genera and Species 95 
 96 
 97 
 98 
The whole number value represents the number of urine specimens in each cohort from 99 
which a given bacterial genus/species was cultured. The (%) is the percentage of the total 100 
urine specimens in each cohort from which a given bacterial genus/species was cultured. 101 
The p-value is the significant value for the Fischer’s Exact Test. The * designates 102 
significance reached for the Pearson Chi-Square Test. 103 
  104 
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Comparison of Urine Culture and 16S rRNA Sequencing Data. 105 
 A subset of the baseline urine specimens subjected to EQUC (29% 30/105) was 106 
also examined by 16S rRNA sequencing. In each of these 30 urine specimens, bacterial 107 
DNA was detected; therefore, they were sequenced. Dr. Meghan Pearce performed all the 108 
sequencing preparation and analyses. 109 
Extensive overlap was observed in terms of the bacterial genera detected with 110 
both sequencing and EQUC (Figure 10). A total of 18 different genera were cultured 111 
with EQUC; all but Trueperella were detected by sequencing. These data provide 112 
additional evidence that the sequenced genera of the urinary microbiome represent live 113 
bacteria that make up the urinary microbiota.  114 
In some urine specimens, EQUC detected genera not detected by sequencing 115 
(Figure 10). Yet, these genera were sequenced in other urine specimens inferring that 116 
they can be amplified with the universal primers used for sequencing. In these particular 117 
urines, the genera detected by EQUC were in CFU concentrations lower than that which 118 
could be detected by sequencing (101-103). 119 
Five genera (Atopobium, Prevotella, Rhodanobacter, Sneathia, and Veillonella) 120 
were only detected by sequencing (Figure 10). These data suggest that EQUC is limited 121 
in its ability to detect these organisms. 122 
  123 
  
39 
 124 
 125 
Figure 10- Comparison of Bacterial Genera Detected by EQUC and 16S rRNA 126 
Sequencing. A comparison of the bacterial genera detected by sequencing and culture of 127 
urine specimens (N=30). Each square was color-coded based on whether the bacterial 128 
genera were detected by sequence only (green), EQUC only (red), sequence and EQUC 129 
(yellow) or neither sequence nor EQUC (grey). 130 
131 
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  132 
ASSOCIATION OF BACTERIAL SPECIES OF THE FEMALE URINARY 133 
MICROBIOTA WITH THE HUMAN UROTHELIUM 134 
 135 
INTRODUCTION 136 
Recent evidence demonstrates the existence of urinary microbiota (Hilt et al., 137 
2014, Pearce et al., 2014). Thus, live bacteria are present in the bladder, but it is not clear 138 
if the bacteria associate with the bladder urothelium. Bacterial species that associate with 139 
the urothelium are of interest because they are more likely to play a role in OAB 140 
symptoms.  141 
Previous studies have shown many uropathogens can attach to and invade 142 
urothelial cells (Coker et al., 2000, Struve et al., 2008, Hunstad & Justice, 2010); 143 
therefore, it is reasonable to hypothesize that some other urinary bacteria do likewise. 144 
This hypothesis is supported by evidence that bacterial species obtained from standard 145 
culture negative patients with lower urinary tract symptoms are closely associated to 146 
urothelial cells (Horsley et al., 2013, Khasriya et al., 2013).  147 
There are two methods one could use in order to identify bacterial species of the 148 
urinary microbiota that associate with the urothelium. The first is to culture bladder 149 
biopsy tissue. The second method to is to examine bacterial communities associating with 150 
shed urothelial cells in urine (Horsley et al., 2013, Khasriya et al., 2013). 151 
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 In the latter experiment, a protocol was developed to optimize the second 1 
method for future study use and to avoid the invasive procedure of a bladder biopsy to 2 
distinguish between the bacterial populations (planktonic, adherent, intracellular) of the 3 
urinary microbiota. The protocol combined three different assays to get an accurate 4 
picture of the different bacterial populations in the urinary microbiota. These three assays 5 
or arms of the protocol are the filtered urine culture (Figure 2), an antibiotic protection 6 
assay (Figure 3) and a tissue-culture adherence assay (Figure 5).  7 
  8 
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RESULTS 9 
Bacterial Species of the Female Urinary Microbiota and Association with Bladder 10 
Biopsy Tissue.  11 
Four sets of bladder biopsies and urines (TUC and SPA) were obtained from 12 
patients undergoing surgery at the Female Pelvic Medicine and Reconstructive Surgery 13 
center of Loyola University Medical Center. All four patient’s urine and biopsy samples 14 
were cultured using EQUC.  15 
Three of the four patients did not have any growth in all the conditions (Table 3). 16 
In contrast, bacteria were cultured from the urines and biopsies of one patient (010) 17 
(Table 3). The TUC and SPA urine specimens contained significant and matching counts 18 
of Klebsiella pneumoniae and Staphylococcus aureus. Both organisms were isolated from 19 
the bladder biopsies, but in lower counts. The bladder biopsies of Patient 010 also grew 20 
additional organisms (Lactobacillus gasseri, Enterococcus faecalis, and Enterococcus 21 
faecium) that were not found in the TUC and SPA samples. The failure to detect these 22 
organisms in the TUC and SPA samples may be due to low CFUs that cannot be detected 23 
with EQUC, and/or the fact that both K. pneumoniae and S. aureus overgrew the plates.  24 
  25 
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Table 3- Bladder Biopsy Tissue Culture Results 26 
27 
28 
 29 
 30 
 31 
 32 
  33 
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Antibiotic Protection Assay’s Ability to Distinguish Between Populations of 34 
Female Urinary Microbiota and their Associations with Urothelial Cells.  35 
 To distinguish between bacteria that associate with shed urothelial cells and 36 
planktonic bacteria, we adapted a previously published antibiotic protection assay 37 
(Khasriya et al., 2013) (Figure 3). This assay also should distinguish between bacteria 38 
associated with the urothelial cells into subpopulations of bacteria that adhere to the cell 39 
surface (PBS arms) and the bacteria that are intracellular (lysed arms) (Figure 3).  40 
A total of 10 practice urine specimens collected via transurethral catheter were 41 
used to optimize this Antibiotic Protection Assay arm (Table 4). These practice urines 42 
were leftover urine specimens destined to be discarded after clinical evaluation of 43 
patients at the Female Pelvic Medicine and Reconstructive Surgery center of Loyola 44 
University Medical Center.  45 
Four of the 10 practice urines (#7, 8, 12, 16) had ‘No Growth’ in any of the 46 
conditions.  However, bacteria were cultured from the other six practice urines and the 47 
assay was able to distinguish between the bacterial species that were planktonic and those 48 
that associated with shed urothelial cells. For example in both practice urines 10 and 11, 49 
106 CFU of Escherichia coli was detected in the EQUC control. Once the urine was 50 
placed through the assay and concentrated, there were 5 and 10 CFU/mL of Escherichia 51 
coli, respectively, suggesting that a large amount of the Escherichia coli in these urine 52 
specimens was planktonic while a small subset associated with the urothelial cells. 53 
Practice Urine 9 (Table 4) had ‘No Growth’ in the control EQUC arm, but 54 
Escherichia coli was detected in low CFU’s once the urine specimen was concentrated 55 
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(PBS-treated). Thus, bacteria can be present in lower CFU counts than the thresholds 56 
for the standard urine culture approach and even the EQUC protocol.  57 
Practice Urine 15 (Table 4) had the same amount of Klebsiella pneumoniae and 58 
Enterococcus faecalis in all three arms of the experiment. Since both organisms were 59 
cultured in the antibiotic-treated arm, antibiotic sensitivities were performed on both 60 
organisms. The Klebsiella pneumoniae and Enterococcus faecalis were both resistant to 61 
the antibiotic cocktail (200 ug/mL Gentamicin, 100 units/mL Penicillin, 100 mg/mL 62 
Streptomycin). This resistance was most likely acquired naturally within the patient or 63 
was present in the bacteria before entering the patient. The resistance exhibited by these 64 
organisms demonstrates the limit of this assay. In this urine, we are unable to distinguish 65 
between bacteria that are planktonic and bacteria that are associated with the urothelial  66 
cell.  67 
  68 
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Table 4- Antibiotic Protection Assay Practice Urine Results 70 
 71 
 72 
Culture results for the antibiotic protection assay for practice urines 7-16. The – 73 
designates a negative or No Growth result of the urine in that arm of the assay. The 74 
number in front of the organism represents the number of colony forming units 75 
(CFU)/mL of urine for which that organism was present.  76 
  77 
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Antibiotic Protection Assay In Detection of Intracellular Bacteria  78 
In the six of 10 practice urines that grew bacterial species, I was able to 79 
distinguish between the bacterial species that were planktonic and those that were 80 
associated with shed urothelial cells. However, from these data, I was unable to 81 
distinguish between bacteria that were attached to urothelial cells and those that were 82 
intracellular. But, a proof of principle assay had not been performed to determine whether 83 
this protocol could detect intracellular bacteria. Therefore, I grew immortalized urothelial 84 
cells and infected them with UPEC, known to be taken up intracellularly by these cells 85 
(Hunstad & Justice, 2010) and then ran the cells with UPEC through the Antibiotic 86 
Protection Assay Arm. If the assay were detecting intracellular bacteria in urothelial cells, 87 
then I would detect UPEC in the antibiotic treatment branch of the assay (Figure 3). 88 
In both instances (Run 1 and Run 2), the Antibiotic Protection Assay Arm did not 89 
detect intracellular UPEC in the immortalized human urothelial cells (Table 5). 90 
However, the Human Urothelial Cell/UPEC Infection Assay arm for Run 1 and Run 2 91 
found an average intracellular count of 330 CFU/mL and 220 CFU/mL of UPEC per 92 
well, respectively. These data suggest that the current Antibiotic Protection Assay is 93 
unable to detect intracellular bacteria. 94 
 95 
 96 
 97 
 98 
 99 
 100 
 101 
 102 
 103 
 104 
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Table 5- Human Urothelial Cell/UPEC Infection Assay Results 105 
 106 
 107 
Summary of the two runs of the proof of principle Human Urothelial Cell/UPEC 108 
Infections Assay. The NG designates a negative or No Growth result for that condition. 109 
The number designates the amount of cells per well cultured in that condition.  110 
  111 
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Adherent vs. Intracellular Bacterial Populations 112 
In order to further differentiate between bacterial populations that either adhere to 113 
the urothelial cell surface or are taken up intracellularly, a total of four urine specimens 114 
were placed through both the antibiotic protection and tissue culture adherence assay 115 
arms of the protocol. The antibiotic protection assay is able to distinguish between 116 
bacteria that are planktonic and bacteria that are associated with the urothelial cells 117 
(Figure 3). The tissue-culture adherence assay arm is designed to further characterize the 118 
bacterial populations that associate with the cells into bacteria that adhere to the cell 119 
surface and the bacteria that are taken up intracellularly (Figure 5).  120 
In the antibiotic protection assay arm, bacteria were detected in all four urine 121 
specimens in the no antibiotic treatment arm (Table 6). All bacterial species detected in 122 
the four urines were also detected in the EQUC control; however, they were detected in 123 
two-three logs lower CFU counts. These data suggest that the bacterial species in the no 124 
antibiotic treatment arm are associated with the shed urothelial cells and are not 125 
planktonic. In the tissue-culture adherence assay, two of the four urine specimens in the 126 
no antibiotic arm were not plated for culture (Table 6). This was due to the fact that the 127 
pH indicator in the tissue culture media had changed, indicating a large amount of cell 128 
debris being present in the wells. 129 
In all four specimens, there was no detection of intracellular bacteria in the 130 
antibiotic protection assay. However, with the tissue-culture adherence assay, bacteria 131 
were cultured from the antibiotic condition in two of the four urine specimens, suggesting 132 
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that the bacteria may have been intracellular (Table 6). To confirm that these 133 
organisms were intracellular, antibiotic sensitivities should have been performed.  134 
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Table 6-Antibiotic Protection and Tissue-Culture Adherence Results 135 
 136 
 137 
 138 
Summary of culture results for practice urines 17-20 using both the antibiotic protection 139 
and tissue-culture adherence assays. The None represents no bacteria were grown in that 140 
culture condition in the assay. The N/A designates the culture was not performed due to 141 
overgrowth of bacteria in the tissue-culture adherence assay. Every practice urine had an 142 
EQUC control culture performed. 143 
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CHAPTER FOUR 1 
 2 
DISCUSSION 3 
The data presented here support the existence of the female urinary microbiota 4 
and further demonstrate differences in the female urinary microbiota in individuals with 5 
and without OAB.  6 
One diagnostic criterion for women who suffer from OAB is a negative standard 7 
urine culture. The implication of the negative standard culture is that the individual does 8 
not suffer from a clinically relevant urinary tract infection and that the symptoms are not 9 
caused by a bacterium (Haylen et al., 2010). However, recent work done by others and 10 
our group support the hypothesis that standard urine culture is not effective in detecting 11 
most of the bacterial taxa present in urine (Khasriya et al., 2013, Hilt et al., 2014). 12 
Khasriya and colleagues (2013) compared standard cultures with cultures of centrifuged 13 
urinary sediment from MV samples from men and women. They were able to culture a 14 
large number of undetected bacteria in the urinary sediment compared to the standard 15 
culture (Khasriya et al., 2013). Our group demonstrated in our recent publication and 16 
here with this work that the standard urine culture had a false-negative rate of ~90% 17 
(Table 1). It is clear that the standard urine culture with a threshold of 105 CFU and 18 
incubation in aerobic conditions for 24 hours is not sufficient for complete and accurate 19 
diagnosis, because it cannot culture a large portion of urinary bacteria. All the evidence 20 
suggests that many culture-negative standard urine cultures are not actually culture- 21 
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negative and demonstrates the need to reevaluate the standard urine culture technique 1 
and to expand it to help women suffering from lower urinary tract disorders other than 2 
UTI.  3 
 Our group is not the first to use an expanded culture condition to suggest the re- 4 
evaluation of the standard urine culture technique. As mentioned in the literature review, 5 
Dr. Rosalind Maskell plated SPA samples on various agar plates and incubated the plates 6 
in a variety of conditions for a longer period of time, a protocol similar to our EQUC 7 
protocol. She was able to culture organisms including Gardnerella vaginalis, 8 
Lactobacillus spp., and fastidious Streptococci (Maskell, 2010). Although specific 9 
species are not mentioned in her text, we found Gardnerella a lot of Lactobacillus and 10 
Streptococcus species in the female urinary microbiota.   11 
The female urinary microbiota in women with OAB are different from the 12 
microbiota of women without OAB. Several bacterial genera were more frequently 13 
cultured from the urine of women with OAB, including Actinobaculum, Actinomyces, 14 
Aerococcus, and Oligella. Interestingly, many of these genera contain emerging 15 
uropathogens, including Actinobaculum schaali, Aerococcus urinae, and Oligella 16 
urethralis (Bank et al., 2010, Zimmermann et al., 2012, Dabkowski et al., 2013, 17 
Rasmussen, 2013), which also were seen more frequently in the urinary microbiota of 18 
women with OAB. Whether these bacteria contribute to OAB is unknown at this time and 19 
requires further research.  20 
Another interesting bacterial species that was more frequently cultured in the 21 
OAB cohort than the non-OAB cohort was Gardnerella vaginalis (Figure 9). This 22 
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bacterium is a facultative anaerobe isolated from the vaginal tract and known to be a 23 
biomarker of the vaginal dysbiosis called bacterial vaginosis (Liu et al., 2013). At this 24 
time, it is not known if the G. vaginalis isolates from the OAB cohort are pathogenic, but 25 
it has been shown previously that G. vaginalis can be cultured from the vaginal tracts of 26 
women with and without bacterial vaginosis (Hyman et al., 2005, Harwich et al., 2010). 27 
More research must be performed to determine if G. vaginalis isolates from both the 28 
OAB and non-OAB cohorts are either pathogenic or symbiotic strains of G. vaginalis. 29 
Intriguingly, the genus Lactobacillus was cultured frequently in both the OAB 30 
and non-OAB cohorts. The bacteria in this genus are lactic acid-producing, facultative 31 
anaerobic bacteria known to play protective roles in the vaginal tract by decreasing pH 32 
and producing various bacteriostatic/cidal compounds (Redondo-Lopez et al., 1990, 33 
Kaewsrichan et al., 2006). However, the Lactobacillus species isolated more frequently 34 
from either cohort was different. L. gasseri was cultured more frequently from the OAB 35 
cohort and L. crispatus was cultured more frequently from the non-OAB cohort (Figure 36 
9). At this time, more research must be performed to determine if this difference is a 37 
consequence of OAB or whether it contributes to OAB symptoms. Stapleton and 38 
colleagues (2011) showed that L. crispatus could be used as a probiotic for recurrent UTI 39 
suggesting that it could play protective role in the female urinary microbiota (Stapleton et 40 
al., 2011). 41 
Finally, these data demonstrate that live culture results match that of sequencing 42 
results (Figure 10). 16S rRNA gene sequencing gives broad view of the urinary bacterial 43 
communities, while culturing live bacteria provides a more focused view.  44 
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The evidence for urinary microbiota is compelling, but whether these bacteria 45 
associate with the bladder urothelium remains uncertain. Bacterial species that associate 46 
with the urothelium are of particular interest because they are more likely to play a role in 47 
OAB symptoms. The bacteria present in the urinary microbiota could associate with the 48 
bladder urothelium in two ways: either (1) by adherence to the surface of the urothelial 49 
cells or (2) by invasion of the urothelial cell. The possibility also exists that some urinary 50 
bacteria are planktonic and do not associate with the urothelium. Such bacteria could 51 
influence the urothelium via secreted products. 52 
There are two methods one could use to identify bacterial species of the urinary 53 
microbiota that associate with the urothelium. The first is to go straight to the source and 54 
culture bladder biopsy tissue; however, this method is invasive and it is difficult to obtain 55 
samples on a regular basis. The second method is to examine bacterial communities 56 
associated with shed urothelial cells in urine (Horsley et al., 2013, Khasriya et al., 2013).  57 
The first method, culture of bladder tissue biopsy, provided some evidence that 58 
the urinary microbiota (or some bacteria in the urinary microbiota) associate with the 59 
human urothelium. I obtained and cultured four sets of bladder biopsy tissue with urine 60 
samples. I was unable to culture any bacteria in the first three samples, including the 61 
urines. However, the bladder tissue biopsies and the urine samples of the fourth patient 62 
yielded similar bacteria (Table 1). Both the urine specimens (TUC and SPA) had large 63 
amounts of Klebsiella pneumoniae and Staphylococcus aureus. A smaller amount of both 64 
organisms were cultured in the bladder biopsy tissue. I do not believe that this is an 65 
artifact of the urine because each tissue is washed twice with saline before being ground 66 
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for culture (as described in Methods and Materials). Other organisms were found in the 67 
bladder biopsy tissue but not in the urine specimens. This is most likely due to 68 
overgrowth of K. pneumoniae and S. aureus. Further work needs to be done to determine 69 
if these bacteria are truly associated with urothelial cells. If so, then one could investigate 70 
this interaction, its effect upon the urothelial cells, and whether any of those effects lead 71 
to OAB symptoms. 72 
Culture of bladder biopsy tissue can provide an accurate picture of the bacteria 73 
that may be associated with the urothelium, but it is an invasive procedure and thus it can 74 
be a challenge to obtain samples. Therefore, to make more rapid scientific progress, it is 75 
important to use another method to identify the bacterial species in the urinary microbiota 76 
that associate with the urothelium. A less invasive approach is to examine shed urothelial 77 
cells in urine (Horsley et al., 2013, Khasriya et al., 2013).  78 
Thus, I developed and attempted to optimize a protocol for future use to 79 
distinguish between the bacterial populations (planktonic, adherent, intracellular) of the 80 
urinary microbiota. The protocol combined three different assays. The first assay was 81 
filtration of the urine to distinguish between planktonic and associated bacteria (Figure 82 
2), the second an antibiotic protection assay to distinguish between planktonic, adherent 83 
and intracellular bacteria (Figure 3), and the third was a tissue-culture adherence assay to 84 
aid in distinguishing between adherent and intracellular bacteria (Figure 5). 85 
The antibiotic protection assay arm of the protocol was able to differentiate 86 
between the planktonic bacteria population and the bacterial populations that associate 87 
with the shed human urothelial cells. In the antibiotic protection assay arm, bacteria were 88 
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detected in some practice urine specimens in the no antibiotic treatment arm (Table 4, 89 
Table 6). All bacterial species detected in the urines were also detected in the EQUC 90 
control; however, they were detected at two-three logs lower CFU counts. These data 91 
suggest that the bacterial species in the no antibiotic treatment arm are associated with the 92 
shed urothelial cells and are not planktonic. 93 
The antibiotic protection assay arm alone could not distinguish between bacteria 94 
that adhere to the urothelial cell surface and intracellular bacteria. In the proof of 95 
principle human urothelial cell/ UPEC infection assay, it was shown that the antibiotic 96 
protection assay could not detect intracellular UPEC in the immortalized human 97 
urothelial cells (Table 5). A modification to this protocol for the future would be to 98 
handle the cells with more care. In addition, it is unknown if adding trypsin in the proof 99 
of principle assay is harmful to the bacterial populations associated with the urothelial 100 
cells. In the control arm of the human urothelial cell/ UPEC infection assay, the cells 101 
were not treated with trypsin (Figure 4). Future control experiments would need to be 102 
performed to determine if trypsin has any effect. 103 
However, this protocol was designed to use multiple assay/arms to obtain a more 104 
complete picture of the different bacterial communities that may associate with the shed 105 
urothelial cells. Some evidence that suggests the tissue-culture adherence arm could help 106 
further distinguish the associated bacterial population into bacteria that are adherent to 107 
the cell surface and intracellular bacteria. In the tissue-culture adherence assay, Dr. 108 
Meghan Pearce was able to detect several bacterial species in the antibiotic treatment 109 
branch that were not detected in the no-antibiotic treatment branch of two urine 110 
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specimens (Practice Urines 18 and 19) (Table 6). These data suggest that these 111 
bacterial species were intracellular.  112 
Overall, these data demonstrate that these two assays complement one another. 113 
The results of the antibiotic protection assay show that it can distinguish between bacteria 114 
that are planktonic and bacteria that are associated with shed urothelial cells. The results 115 
of the tissue-culture adherence assay show that it can take the distinction one step further 116 
and thus distinguish between bacteria that may be adherent and bacteria that may be 117 
intracellular. 118 
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